Genetics and Obesity: How Genes Can Influence Body Weight

• Answers the question directly, then explains why genes cannot account for the rise in obesity over recent decades.
• Separates the three genuinely different kinds of genetic contribution, which most explanations run together.
• Puts a real number on the best known obesity gene, and it is far smaller than most people assume.
• Covers when genetic testing is actually appropriate, and the one licensed UK treatment for rare genetic causes.

Yes, obesity is substantially genetic, but there is no single “obese gene” for common obesity. Studies of twins and families consistently find that inherited factors explain a large share of the differences in body weight between people, yet for most adults this risk comes from hundreds of gene variants, each with a small effect; even the best-known variant, FTO, is linked to less than one BMI point difference on average.

But that answer, on its own, misleads in two directions. It can sound like a life sentence, and it is not. It can also suggest that one gene determines body weight, when the real picture is a mix of polygenic risk, environment and behaviour, with rarer single-gene and syndromic forms affecting a small number of people.

For adults in the UK trying to make sense of weight, treatment choices or whether DNA testing is worth it, two findings are worth understanding before anything else. Most obesity-associated genes appear to affect appetite more than metabolic rate, which is the opposite of what many people assume, and genetic risk does not mean treatment cannot help.

This page explains how genes influence body weight, the difference between monogenic, syndromic and polygenic obesity, how much the FTO gene actually matters, when genetic testing is appropriate, which licensed treatments exist for rare genetic obesity, and why DNA-based diet tests have limited practical value. Getting clear on this helps you separate myth from evidence, understand why genetics cannot explain the recent rise in obesity on their own, and make better decisions about weight loss treatments.

Key things to know

• Inherited factors explain a large share of why people differ in body weight, commonly estimated between 40 and 70 per cent depending on how it is studied, and obesity affects over 650 million adults worldwide.
• Genes explain differences between people living in the same environment. They cannot explain the rise in obesity over recent decades, because populations have not changed genetically in that time.
• There is no single obesity gene for the common form. Hundreds of variants each contribute a very small amount.
• The best known variant, in a gene called FTO, is associated with a difference of well under one BMI point between people carrying two copies and none.
• Most obesity-associated genes act in the brain on appetite and fullness, not on metabolic rate.
• Rare single gene causes exist, usually producing severe obesity and intense hunger from early childhood. These are the cases where genetic testing matters.
• Higher genetic risk does not make weight management less effective, although obesity increases the risk of diabetes, heart disease, and stroke, as well as other serious diseases.
• One medicine is licensed in the UK for specific rare genetic causes, and it is explicitly not indicated for common obesity.

Is obesity genetic?

Substantially, yes. Inherited factors explain a large proportion of why two people in similar circumstances end up at different body weights.

How much of the variation is genetic?

Estimates commonly fall between 40 and 70 per cent, varying with study design. Twin studies tend to produce figures at the higher end, family and adoption studies somewhat lower.

The word "variation" is doing important work in that sentence. Heritability describes how much of the difference between people in a population is explained by genetic differences. It does not describe how much of any individual's weight is genetic, and it is not a percentage of you.

Why can genes not explain the rise in obesity?

Gene pools do not change enough over a few decades to explain the rapid rise in obesity. Obesity rates in the UK have increased substantially since the 1990s, while the population's genetic makeup has not changed on anything like that timescale.

What changed was the environment and other environmental factors: food availability, portion sizes, cost, marketing, working patterns and daily physical activity. Genes determine who is most affected by that environment. The environment determines how many people are affected at all. Environmental exposures and other environmental influences can influence gene expression through epigenetic modifications without altering DNA sequence, and maternal undernutrition during pregnancy can increase obesity risk in offspring.

This is the single most useful idea in the whole topic. Genes explain the differences between individuals. The environment explains the change over time. Both are true at once, and neither cancels the other.

The three kinds of genetic obesity

Genetic contribution comes in three genuinely different forms, and running them together is where most confusion starts.

What is monogenic obesity?

Monogenic means a change in a single gene is enough to cause the condition. In obesity, these changes usually affect the leptin melanocortin pathway in the brain, which helps govern hunger, fullness, appetite regulation, and energy homeostasis.

The recognisable picture is severe obesity beginning in the first few years of life, with hyperphagia, meaning a persistent and intense hunger that is much greater than normal and does not settle after eating. Leptin is produced mainly by white fat cells in adipose tissue and helps regulate appetite control, food intake, and energy expenditure.

Leptin deficiency is a rare form of monogenic obesity and can cause severe hyperphagia and rapid weight gain beginning in early infancy.

Genes involved include those coding for leptin, the leptin receptor, POMC and PCSK1, and MC4R, which is the most common gene associated with monogenic obesity. MC4R is one of the most common genes implicated in monogenic obesity. Pathogenic MC4R variants are particularly associated with severe, early-onset obesity, but they remain uncommon among people with obesity overall.

These causes are rare, but they matter disproportionately because some of them are now treatable.

What is syndromic obesity?

Syndromic obesity means obesity occurs as one feature of a broader genetic syndrome that also affects other systems. Prader-Willi syndrome occurs in about 1 in 15,000 births, and Prader-Willi syndrome and Bardet-Biedl syndrome are the best known examples.

The distinguishing feature is that obesity does not appear alone. There are usually developmental features, learning difficulties, behavioural problems, or cognitive impairment that help define the clinical features and lead to the diagnosis being considered. In Bardet-Biedl syndrome, these may also include retinal dystrophy, rod-cone dystrophy, and renal abnormalities.

What is polygenic obesity?

Polygenic means many genes, each contributing a small amount. This is the form that applies to the overwhelming majority of people with obesity, and much of what we know about it comes from genome-wide association studies.

Hundreds of common genetic variants have been associated with body weight. Individually their effects are tiny. Collectively they produce a spread of susceptibility across the population, so that in the same environment some people gain weight readily and others do not. Rare variants also contribute in a small fraction of cases.

The risk of obesity in polygenic obesity reflects many small inherited effects interacting with environmental factors. Findings are strongest in studies of European ancestry, and there can be significant heterogeneity across populations.

There is no threshold and no diagnosis here. Polygenic susceptibility is a continuum that everyone sits somewhere on.

Is there an "obesity gene"?

Not for common obesity. The gene most often described that way is FTO, and its effect is far smaller than its reputation suggests.

How big is the FTO effect?

Small enough to be worth stating precisely. Each copy of the higher-risk version is associated with roughly 0.4 BMI points on average. The corresponding difference in body weight depends on height, but for an average-height adult it is roughly around 1 kg.

A large UK study of more than 120,000 people illustrates this well. Average BMI was around 27.3 in people carrying no copies of the higher-risk version, around 27.5 in those carrying one, and around 28.1 in those carrying two.

That is a difference of well under one BMI point between having none and having two copies of the most famous obesity gene there is. It is a real effect and it is statistically solid, but it is nothing like what "I have the obesity gene" implies.

So why do people say they have the obesity gene?

Usually because a consumer test or an article has reported a variant without its effect size. A variant can be genuinely associated with body weight and still shift it by an amount you would never notice.

The honest summary is that no single common variant explains anyone's weight. Susceptibility comes from the accumulation of many small effects, and even the total is a tendency rather than a determinant.

What do these genes actually do?

Most of them act in the brain, on appetite and fullness. Very few act on metabolic rate. This is the finding that most contradicts what people expect.

Is it about a slow metabolism?

Not primarily. Many of the strongest genetic signals associated with common obesity point to brain pathways involved in hunger, fullness, food reward and energy homeostasis rather than directly controlling resting metabolic rate.

In practical terms, inherited susceptibility tends to show up as feeling hungrier, feeling full later, finding food more rewarding, and responding more strongly to the sight and smell of food. Leptin resistance is also common in obesity, meaning the brain does not respond normally to leptin signals. It does not typically show up mainly as burning fewer calories at rest, but rather through altered regulation of food intake and energy expenditure.

Why does that distinction matter?

For three reasons.

• It explains the experience. People often describe struggling with hunger rather than with willpower, and describe it as feeling different from how others seem to experience eating. That description matches the biology.
• It points at what works. If the inherited difficulty is appetite regulation, then approaches that act on appetite, whether through eating patterns, food composition, sleep, or medicines that act on appetite signalling, are working on the actual mechanism. It also helps to reduce exposure to high calorie foods, which can make it easier to avoid taking in more calories than needed.
• It changes the moral framing.A stronger appetite drive is not a character flaw. Recognising it as a physiological difference is more accurate and more useful than treating it as a failure of discipline.

Does genetic risk mean treatment will not work?

No. This is one of the more encouraging findings in the area, and it is consistently reported.

People with higher genetic susceptibility to obesity respond to weight management approaches broadly as well as people with lower genetic susceptibility. Higher genetic susceptibility is associated with an increased risk of obesity, not with a smaller response to intervention.

The practical reading is straightforward. Genetic susceptibility helps explain how someone arrived at their current weight. It does not predict how they will respond to doing something about it, and it is not a reason to expect failure.

Results vary between individuals for many reasons, and genetics is only one of them. It also does not reliably predict a poorer weight loss response.

When is genetic testing appropriate?

Rarely, and for specific reasons. Genetic testing is not useful for ordinary obesity, because polygenic susceptibility is spread across hundreds of variants and knowing your score would not change what anyone does.

What features suggest a genetic cause worth investigating?

• Severe obesity develops in the first few years of life, particularly before the age of five; MC4R deficiency is one of the more common single-gene causes and accounts for about 2% to 6% of severe obesity cases.
• Hyperphagia: intense, persistent hunger that is clearly out of proportion and does not settle after eating.
• A strong family history of severe early-onset obesity, or parents who are related to each other.
• Developmental delay or learning difficulties alongside obesity, especially when behavioural problems are also present.
• Distinctive physical features, or problems affecting vision, hearing or the hormonal system, including retinal dystrophy and renal abnormalities in some syndromic conditions.
• ● Obesity that begins after an injury, surgery, tumour or other condition affecting the hypothalamus should also be discussed with a specialist, although this suggests acquired hypothalamic obesity rather than a genetic cause.

What does assessment involve?

Assessment typically covers when the weight gain started, the pattern and severity of hunger, family history, BMI, examination for associated features and appropriate investigations to exclude other causes. Where the clinical picture suggests a genetic cause, genetic testing may include targeted testing or a broader gene panel and, in selected cases, exome sequencing.

The purpose is not curiosity. It is that a small number of these diagnoses change what treatment is available, so your specialist clinician can advise on next steps and signpost you for further information.

Is there a treatment for genetic obesity?

For a small number of rare causes, yes. Setmelanotide is licensed in the UK for the treatment of obesity and the control of hunger in specific genetically confirmed conditions.

What is it licensed for?

It acts on the MC4 receptor within the leptin–melanocortin pathway. In the UK, its authorised indications include genetically confirmed POMC deficiency, including PCSK1 deficiency, LEPR deficiency and Bardet-Biedl syndrome, as well as acquired hypothalamic obesity caused by hypothalamic injury or impairment.

In a small open-label study of children aged 2 to under 6 years, mean BMI fell by about 25.6% at 52 weeks in children with POMC or LEPR deficiency and by about 9.7% in those with Bardet-Biedl syndrome. Because the study was small and uncontrolled, these results should be interpreted cautiously.

Who is it not for?

Almost everyone. It is explicitly not indicated for common polygenic obesity, for obesity associated with other genetic syndromes, or where a suspected variant has been classified as benign or likely benign.

This is worth stating plainly, because "there is a medicine for genetic obesity" is easy to misread. There is a medicine for a small number of specific, genetically confirmed conditions, prescribed through specialist centres after genetic confirmation. It is not a treatment anyone can seek on the basis of a family history or a consumer test result.

Setmelanotide is subject to additional monitoring, and suspected side effects should be reported through the MHRA Yellow Card scheme. This medicine should only be used under the supervision of an appropriately qualified prescriber.

What about DNA-based diet tests?

Consumer tests offering a diet or exercise plan based on your genetics are not supported by good evidence, and buying one is unlikely to tell you anything useful.

There are two problems. Polygenic scores predict poorly at the level of an individual, even when they work well across a population, so your personal score has limited meaning. And no test has convincingly shown that matching a diet to a genetic profile produces better results than a diet chosen for any other reason.

A test that reports which variants you carry is describing a small statistical tendency. It is not diagnosing anything, it does not identify the rare single gene causes described above without proper clinical assessment, and it should not change what you do.

What this means in practice

The practical conclusions are more useful than the science might suggest.

• Your genetics may explain why this is harder for you than for someone else. That is a legitimate explanation, not an excuse, and it is supported by evidence.
• It does not predict what happens next. Higher genetic risk does not reduce how well weight management works.
• The mechanism is mostly appetite. Approaches that address hunger and fullness are working on the real problem.
• Family history is worth knowing. Not for testing, but because it tells you your susceptibility is likely higher and prevention effort is worth applying earlier.
• Testing is for a specific picture. Severe obesity from early childhood with intense hunger, or obesity alongside developmental features, is worth raising with a doctor.

Where does the treatment fit?

Licensed weight-management medicines have specific eligibility criteria that vary by medicine. Some are authorised for adults with a BMI of 30 kg/m² or above, while others may be used from a BMI of 27 kg/m² when weight-related health problems are present. Your prescriber will assess whether a particular medicine is appropriate for you.

Meeting a threshold is not the same as being suitable. Treatment suitability depends on an individual clinical assessment, and your prescriber will determine the appropriate treatment. If you want to understand which options might apply to you, an online consultation with UK registered prescribers is a reasonable place to start. If your history includes the features described above, speak to your GP about specialist assessment instead.

Medical Disclaimer

This article is for general information and does not replace personalised medical advice. It cannot diagnose obesity, any genetic condition, or determine anyone's genetic risk, and genetic testing should be arranged through a clinician rather than interpreted from a consumer test. Prescription only medicines should be used only under the supervision of an appropriately qualified prescriber, following a clinical assessment, and results vary between individuals. Medicines licensed for rare genetic causes of obesity are prescribed through specialist services after genetic confirmation and are not appropriate for common obesity. If you take a prescribed medicine, follow the patient information leaflet supplied with it, never take extra to make up for a missed dose, and do not stop a prescribed medicine without discussing it with the prescriber. Report suspected side effects through the MHRA Yellow Card scheme, and seek urgent medical attention for severe or rapidly worsening symptoms.